ReviewPharmaceutics2023
IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa.
Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Efficacy and safety of biologics for hidradenitis suppurativa: A network meta-analysis of phase III trials.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Pooled it
- Molecular Characteristics of Sweet Syndrome: A Systematic Review.Experimental dermatology · 2024Pooled it
- Efficacy and safety of two interleukin-17 inhibitors (bimekizumab and secukinumab) in the management of hidradenitis suppurativa: a systematic review and meta-analysis of randomized controlled trials.Skin health and disease · 2026Review
- Spatial transcriptomics maps early B-cell and T-cell activation in hidradenitis suppurativa.The Journal of investigative dermatology · 2026Article
- Hidradenitis Suppurativa and IL-17 Inhibitors: A Focus on Trials and Real-Life Data.Medicina (Kaunas, Lithuania) · 2026Review
- Article
- Association Between E-FABP Levels, Disease Severity, and Metabolic Parameters in Hidradenitis Suppurativa.Dermatology practical & conceptual · 2026Article
- Efficacy of Secukinumab in Chinese Patients with Moderate-to-Severe Hidradenitis Suppurativa: A 16-Week, Single-Center, Prospective, Real-World Study.Journal of inflammation research · 2026Article
- Hidradenitis suppurativa, from basic science to surgery and a new era of tailored targeted therapy: An expert opinion paper.Archives of dermatological research · 2025Review
- IRAK4 Targeting: A Breakthrough Approach to Combat Hidradenitis Suppurativa.Biologics : targets & therapy · 2025Review
- Case Report: Treating one autoimmune disease induces another: the paradox of TNF-alpha inhibitor therapies.Frontiers in immunology · 2025Article
- Bimekizumab for Hidradenitis Suppurativa from Trials to Real Life: A Review of the Published Literature.Clinical, cosmetic and investigational dermatology · 2025Review
- Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study.Dermatology practical & conceptual · 2024Article
- IL-17 in wound repair: bridging acute and chronic responses.Cell communication and signaling : CCS · 2024Review
- Therapeutic Potential of IL-1 Antagonism in Hidradenitis Suppurativa.Biomolecules · 2024Review
- Golimumab and certolizumab pegol for the treatment of hidradenitis suppurativa: a literature review and future perspective.Therapeutic advances in chronic disease · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a significant negative impact on the quality of life of patients. To date, the therapeutic landscape for the management of the disease has been extremely limited, resulting in a profound unmet need. Indeed, adalimumab, an anti-tumor necrosis factor (TNF)-α monoclonal antibody, is the only approved biologic agent for HS, obtaining a therapeutic response in only 50% of HS patients. Numerous clinical trials are currently ongoing to test novel therapeutic targets in HS. The IL-17-mediated cascade is the target of several biologic agents that have shown efficacy and safety in treating moderate-to-severe HS. Both bimekizumab and secukinumab, targeting IL-17 in different manners, have successfully completed phase III trials with promising results; the latter has recently been approved by EMA for the treatment of HS. The aim of this review is to summarize the current state of knowledge concerning the relevant role of IL-17 in HS pathogenesis, highlighting the key clinical evidence of anti-IL-17 agents in the treatment of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.